ReviewFrontiers in immunology2025
Cerebral rheumatoid vasculitis: an integrated analysis of case presentation, literature review, and prognostic stratification.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cerebrospinal fluid cellular and inflammatory profiles in tumor-related postoperative infections: influencing factors and clinical features in oncological patients.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study integrated a comprehensive literature review spanning from 1951 to 2025 with a histologically confirmed case of cerebral rheumatoid vasculitis (CRV) in order to improve the management of this rare and severe complication of rheumatoid arthritis (RA). By analyzing 37 CRV cases, we observed a striking decline in mortality after the 1980s, with an odds ratio (OR) of 33.07. The combination of immunosuppressants and corticosteroids significantly enhanced treatment outcomes, showing 81.8% efficacy compared to a 63.6% mortality rate without immunosuppressants. Based on these findings, we developed the CRV diagnostic workflow to aid early detection. Our results emphasize the importance of vigilance for neurological symptoms in RA patients and highlight the need for future research to optimize treatment protocols and reduce long-term disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.